Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrimXMAD:PRM 76 EV-to-EBIT is 9.78 as of Jul. 16, 2026, which is 6% below its 10-year median of 10.40. GuruFocus rates XMAD:PRM with a GF Score™ of 76/100 and a GF Value™ of €7.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Prim ranks better than 79.14% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Prim's Enterprise Value is €218.6 Mil.
Prim's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €22.3 Mil. Therefore, Prim's EV-to-EBIT for today is 9.78.
The historical rank and industry rank for Prim's EV-to-EBIT or its related term are showing as below:
XMAD:PRM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.04 Med: 10.4 Max: 1559.46
Current: 9.78
During the past 13 years, the highest EV-to-EBIT of Prim was 1559.46. The lowest was 7.04. And the median was 10.40.
XMAD:PRM's EV-to-EBIT is ranked better than 79.14% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.93
vs XMAD:PRM: 9.78
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Prim's Enterprise Value for the quarter that ended in Dec. 2025 was €217.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €22.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prim EV-to-EBIT Related Terms
Prim EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Prim's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PRM vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Prim's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prim EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prim's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Prim's EV-to-EBIT falls into.
Prim's current Enterprise Value is €218.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €22.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prim (XMAD:PRM) has a EV-to-EBIT of 9.78 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Prim and its competitors. This is near median its historical median of 10.40. Over the past decade, Prim's EV-to-EBIT has ranged from 7.04 to 1,559.46. According to the industry distribution chart, Prim ranks #97 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is Prim's EV-to-EBIT too high?
Prim's current EV-to-EBIT of 9.78 is near median its 10-year median of 10.40. Over the past 10 years, this metric has ranged from a low of 7.04 to a high of 1,559.46. The Medical Devices & Instruments industry median EV-to-EBIT is 18.93. Prim's value of 9.78 is 48.3% below this industry median. Based on the distribution chart, Prim ranks #97 out of 465 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prim has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prim's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prim ranks #97 out of 465 companies for EV-to-EBIT. This places Prim in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.93. Prim's value of 9.78 is 48.3% below this benchmark. Historically, Prim's own EV-to-EBIT has ranged from 7.04 to 1,559.46 over the past decade. While the company's 10-year median is 10.40 vs. the industry median of 18.93, Prim has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.93, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prim's current EV-to-EBIT of 9.78 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Prim and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prim's current EV-to-EBIT is 9.78, which is near median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prim stock overvalued right now?
Based on GuruFocus' analysis, Prim (XMAD:PRM) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.91, compared to a current price of €13.30 — trading 68.1% above its estimated fair value. The current EV-to-EBIT is 9.78, which is near median its 10-year median of 10.40 and 48.3% below the Medical Devices & Instruments industry median of 18.93. Prim's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Prim (XMAD:PRM), the current EV-to-EBIT is 9.78 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prim (XMAD:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Prim stock appears to be overvalued.
The current stock price of €13.30 is trading 68.1% above its estimated GF Value™ of €7.91.
GuruFocus considers Prim to be Significantly Overvalued.
Key valuation signals for XMAD:PRM:
EV-to-EBIT: 9.78 (near median its 10-year median of 10.40)
GF Value™: €7.91 vs. price of €13.30 (68.1% above fair value)
Industry Position: 48.3% below the Medical Devices & Instruments median (#97 of 465)
No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
76GF Score
Get the complete analysis for XMAD:PRM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PRM has been successfully added to your 
